FTC Tastes Sweet Victory in POM Wonderful Deceptive Advertising Appeal

by Mintz Levin

The District of Columbia Circuit Court of Appeals handed the Federal Trade Commission a critical win on January 30, 2015 by affirming the Commission’s January 2013 decision holding POM Wonderful LLC in violation of the FTC Act for its deceptive advertisements alleging pomegranate juice and supplements could treat, prevent, or reduce the risk of heart disease, prostate cancer, and erectile dysfunction. The decision shows the continued reach of the FTC into the scientific bases for health-related advertising, the extensive deference courts give to the agency’s expertise, and that substantive disclaimers may be the only way to avoid liability.

Background: A Quick Glance at POM Wonderful

Since 1998, POM has invested over $35 million in over 100 studies at 44 institutions to discover and promote the health benefits of pomegranates. In particular, POM claimed that its juices and supplements could treat, prevent, or reduce the risk of heart disease, prostate cancer, and erectile dysfunction.

POM ad campaigns from 2006 to 2009 trumpeted results showing that daily consumption of pomegranate juice increased blood flow by up to 30% in one year. The study underlying that claim assessed 19 participants, showing statistically insignificant, preliminary results that were later disputed by two subsequent, larger POM-funded studies. A $1 million campaign placing 70 ads in publications nationwide claimed a reduction in arterial plaque and better blood flow based on the same study.

Another national ad campaign from 2007 to 2009 stated that drinking POM would slow the growth of prostate cancer, reducing PSA doubling times from 15 to 54 months. The study serving as the basis for these statements, however, was conducted without a control group and with a population of patients who had already either had radical surgery or endured radiation or cryotherapy to slow cancer growth, likely biasing the results.

During the same period, POM issued press releases and ran a series of ads touting the pomegranate’s ability to improve erectile function simply by drinking an eight-ounce glass of juice. POM cited a commissioned crossover study analyzing 53 patients in eight weeks that ended with inconclusive results on an international standard of measure for erectile dysfunction.

After a lengthy investigation, the FTC filed an administrative complaint in September 2010 against POM for its heart disease, prostate cancer, and erectile dysfunction claims. The administrative judge found 19 ads in violation of the FTC Act. On appeal, the full Commission found 36 ads in violation and issued a three-part order for injunctive relief, including (1) a prohibition on representations that POM juice or supplements could prevent or treat any disease, including heart disease, prostate cancer, and erectile dysfunction, (2) a requirement that future disease-specific claims are substantiated by two randomized and controlled human clinical trials (RCTs), (3) a prohibition on misrepresentations of disease-specific scientific studies, and (4) a bar on general health statements without “competent and reliable scientific evidence.”

DC Circuit Court Decision: Deferring to the Commission

The Court reaffirmed its prior holdings granting deference to the agency in fact-finding and the Commission’s adjudicatory decisions. The Court stated that the factual findings of the Commission were “conclusive,” that whether the ad was an efficacy ad or establishment ad was “a question of fact the evaluation of which is within the FTC’s peculiar expertise,” and that the Commission’s legal conclusions need only be “supported by substantial evidence on the record as a whole.” The Court recognized that the Commission’s findings, so long as they are supported by the evidence, are binding, noting that the agency is often more capable of determining when an ad is “deceptive” within the confines of the FTC Act. This highly deferential standard on both the facts and the law essentially adopts the Commission’s findings without independent review.

In its analysis, the Court employed a three-step inquiry, echoing the agency’s analysis, to determine whether the advertisements were deceptive under the FTC Act: (1) what claims are conveyed in the ad, (2) whether those claims are false, misleading, or unsubstantiated, and (3) whether the claims are material to prospective consumers. Materiality was not in dispute.

The Court’s determination of the claims conveyed in the ads began with a discussion of whether the claims were considered efficacy or establishment claims. Efficacy claims suggest that the product performs as advertised, but without any suggestion of scientific evidence of its effectiveness. To defend its efficacy claims, a company need only possess a reasonable basis to uphold the claim. Establishment claims, on the other hand, are ads suggesting that the product’s effectiveness or superiority has been scientifically proven. For these more specific claims, courts (and the agency) impose heightened scrutiny, including evidence that satisfies the relevant scientific community that the claim is true. Essentially, it is the difference between saying “pomegranates are good for you” and “pomegranates cure cancer.”

Here, the Court found that the ads were subject to more exacting scrutiny as establishment ads due to the specific disease-related claims. As the Commission found and the Court affirmed, 34 ads stated that clinical studies proved POM products could treat, prevent, or reduce the risk of heart disease, prostate cancer, and erectile dysfunction. The ads did not just describe the research to allow the customer to determine the validity of their health claims, but instead suggested that the studies were convincing proof of efficacy — and the Court accordingly required more scientific proof.

The Court’s analysis focused primarily on the second step of the inquiry and upheld the FTC’s determination that the claims were unsubstantiated. The studies could not serve as the basis for the claims in the ads because they suffered from several fatal flaws, including an insufficient sample size, a biased population, and statistically insignificant results. These flawed studies, according to the Court, would not live up to any standard in the medical community to provide a basis for POM’s statements. As a result, the ads were unsubstantiated and in violation of the FTC Act.

Despite the overwhelmingly favorable ruling for the FTC, the Court knocked down the section of the FTC’s order requiring that POM substantiate each of its disease-specific health claims with two RCTs. As part of its First Amendment analysis to determine whether the FTC’s order overly restricted POM’s right to free commercial speech, the Court found that, though the government had a substantial interest in curbing commercial misinformation and requiring an RCT was “perfectly commensurate” with that interest, ordering two RCTs was not a “reasonable fit.” Requiring more than one RCT was not the least restrictive way to justifiably constrain POM’s commercial speech because it imposed an additional burden without any further scientific certainty that would quell concerns that POM’s ads were misleading or unsubstantiated.


This decision yields two critical takeaways: (1) courts are highly deferential to the agency’s adjudicative decisions under its own laws, adopting the Commission’s opinion almost entirely; and (2) substantive disclaimers may allow advertisers to trumpet health-related claims without requiring RCTs.

First, the Court’s repeated deference to the Commission on both the facts and the law demonstrates the influence that the Commission’s internal adjudicative process has on the outcome of a case. Without conducting an independent analysis and instead relying almost entirely on the agency’s determinations, the Court only serves to augment the agency’s expanding reach into health-related advertising cases.

In all aspects of this case, the Court deferred to the agency’s holdings. At one point, the Court confirmed that the law “does not permit the reviewing court to weigh the evidence” but only to determine whether it supports the legal conclusion. This essentially provides the Commission with carte blanche to enforce the FTC Act against potentially deceptive advertisements with little oversight. It is unlikely the agency would rather seek a federal district court for its initial enforcement efforts when its internal adjudicative process can yield such positive results with less risk of an unfavorable decision. Such a standard makes the FTC’s administrative “home court advantage” even stronger and even more challenging for those facing investigation and administrative proceedings before the Commission.

Second, despite an otherwise overwhelmingly favorable outcome for the Commission, industry was given some significant guidance that substantive disclaimers may allow advertisers to trumpet health-related claims without requiring RCTs. Though the Court made it more difficult for advertisers to soften the language in order to avoid FTC scrutiny, it provided another mechanism for asserting health-related claims. Calling a study “preliminary” or “initial” is no longer sufficient; instead, a “substantive disclaimer” may be required, such as a statement that “evidence in support of this claim is inconclusive.” But the Court allowed a gaping exception that companies “still may assert health-related claim[s] backed by medical evidence falling short of an RCT if it includes an effective disclaimer disclosing the limitations of the supporting research.”

One of the Court’s main complaints with POM’s advertising was that it cherry-picked favorable studies without reference to more scientifically stringent studies with opposite outcomes. By adequately describing the deficiencies of the product, companies can avoid shelling out for expensive clinical trials to substantiate their advertising claims. This will allow companies seeking to compete in a market increasingly focused on fitness to tout the health benefits of their products while successfully avoiding agency second-guessing.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Mintz Levin | Attorney Advertising

Written by:

Mintz Levin

Mintz Levin on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.